Literature DB >> 16956918

Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt.

D Marzouk1, J Sass, I Bakr, M El Hosseiny, M Abdel-Hamid, C Rekacewicz, N Chaturvedi, M K Mohamed, A Fontanet.   

Abstract

BACKGROUND AND AIMS: To investigate the relationship between lipid profiles and diabetes with past and chronic hepatitis C virus (HCV) infection among village residents of Egypt. PATIENTS AND METHODS: Fasting lipids and glucose profiles were compared among adults never infected with HCV (negative HCV antibodies), infected in the past (positive HCV antibodies and negative HCV RNA) and chronically infected (positive HCV antibodies and HCV RNA).
RESULTS: Of the 765 participants, 456 (59.6%) were female, and median age was 40 (range 25-88) years. Chronic HCV infection was present in 113 (14.8%) and past infection in 67 (8.8%). After adjustment for age and sex, participants with chronic HCV infection had lower plasma low density lipoproteins (LDL) cholesterol and triglyceride levels compared with those never infected (age and sex adjusted differences (95% CI) were -19.0 (-26.3 to -11.7) mg/dl and -26.2 (-39.0 to -13.3) mg/dl, respectively). In contrast, participants with cleared HCV infection had higher triglyceride levels compared with those never infected (age and sex adjusted difference (95% CI) was +16.0 (0.03 to 31.9) mg/dl). In multivariate analysis, participants with chronic HCV infection were more likely to have diabetes (OR 3.05, 95% CI 1.19 to 7.81) compared with those never infected, independent of LDL cholesterol levels.
CONCLUSION: In conclusion, this community based study has shown that in a single population, chronic HCV infection is associated with glucose intolerance and, despite that, a favourable lipid pattern. An intriguing finding was the high triglyceride levels observed among participants with past infection, suggesting that elevated triglycerides at the time of acute infection may facilitate viral clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956918      PMCID: PMC1955512          DOI: 10.1136/gut.2006.091983

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

Authors:  L Serfaty; T Andreani; P Giral; N Carbonell; O Chazouillères; R Poupon
Journal:  J Hepatol       Date:  2001-03       Impact factor: 25.083

2.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

3.  Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus.

Authors:  Mohamed Abdel-Hamid; Mai El-Daly; Sherif El-Kafrawy; Nabiel Mikhail; G Thomas Strickland; Alan D Fix
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.

Authors:  J K Kim; J J Fillmore; Y Chen; C Yu; I K Moore; M Pypaert; E P Lutz; Y Kako; W Velez-Carrasco; I J Goldberg; J L Breslow; G I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

5.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis.

Authors:  Gabriel Perlemuter; Abdelmajid Sabile; Philippe Letteron; Giovanna Vona; André Topilco; Yves Chrétien; Kazuhiko Koike; Dominique Pessayre; John Chapman; Giovanna Barba; Christian Bréchot
Journal:  FASEB J       Date:  2002-02       Impact factor: 5.191

6.  Reference ranges of lipids and apolipoproteins in pregnancy.

Authors:  W Piechota; A Staszewski
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1992-06-16       Impact factor: 2.435

7.  Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C.

Authors:  M Naeem; B R Bacon; B Mistry; R S Britton; A M Di Bisceglie
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

8.  Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population.

Authors:  M E Allison; T Wreghitt; C R Palmer; G J Alexander
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

9.  High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study.

Authors:  M A Darwish; R Faris; J D Clemens; M R Rao; R Edelman
Journal:  Am J Trop Med Hyg       Date:  1996-06       Impact factor: 2.345

10.  C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.

Authors:  M J Prior; T Prout; D Miller; R Ewart; D Kumar
Journal:  Ann Epidemiol       Date:  1993-01       Impact factor: 3.797

View more
  32 in total

1.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

2.  Do high lipids help clearance of hepatitis C?

Authors:  Stephen Ryder
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

3.  Metabolic investigations in patients with hepatitis B and C.

Authors:  Abdul Aziz Mastoi; Bikha Ram Devrajani; Syed Zulfiquar Ali Shah; Qasim Rohopoto; Sikander Ali Memon; Marya Baloch; Ghulam Ali Qureshi; Waqas Sami
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

4.  Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection.

Authors:  Robert J Wong; Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-05

Review 5.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

6.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

8.  Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.

Authors:  Kathleen E Corey; Erin Kane; Craig Munroe; Lydia L Barlow; Hui Zheng; Raymond T Chung
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 9.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

10.  Injection drug use is a risk factor for HCV infection in urban Egypt.

Authors:  Adela Paez Jimenez; Mostafa K Mohamed; Noha Sharaf Eldin; Hasnaa Abou Seif; Said El Aidi; Yehia Sultan; Nasr Elsaid; Claire Rekacewicz; Mostafa El-Hoseiny; May El-Daly; Mohamed Abdel-Hamid; Arnaud Fontanet
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.